Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.52 |
| ▸ | HTR1A | P08908 | 6/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4384778 | 0.99 | HTR7 (0.51) | HTR7HTR1ASIGMAR1MAPTALDH1A1 | |
| SCHEMBL8212151 | 0.89 | KMT2A (0.45) | MAPTALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL8221599 | 0.89 | KMT2A (0.45) | MAPTALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL8218596 | 0.88 | KMT2A (0.48) | SMN1; SMN2KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL4383617 | 0.88 | KMT2A (0.44) | MAPTALDH1A1KMT2ALMNAPOLB | |
| Hydrochloric Acid SCHEMBL4376998 | 0.88 | KMT2A (0.45) | MAPTALDH1A1KMT2ALMNAPOLB | |
| Hydrochloric Acid SCHEMBL4387884 | 0.88 | KMT2A (0.48) | SMN1; SMN2KMT2ALMNA | |
| SCHEMBL4393097 | 0.88 | KMT2A (0.43) | HTR7HTR1AMAPTALDH1A1KMT2A | |
| SCHEMBL8218080 | 0.86 | CHRM4 (0.45) | SIGMAR1DRD2KMT2A | |
| SCHEMBL8210795 | 0.86 | TACR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | HTR7 1303/4885HTR1A 768/4885SIGMAR1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.